G01N 2800/127
Bronchitis
G01N2800/127 (Bronchitis) appears on 11 US grants and 21 published applications in this corpus.
Search patents in G01N- Granted patents
- 11
- Published applications
- 21
- Assignees
- 10
- Inventors
- 23
- Latest grant
- 19 Nov 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 1 | 2 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 1 | 1 |
| 2011 | 1 | 1 |
| 2012 | 0 | 3 |
| 2013 | 2 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 1 | 0 |
| 2019 | 0 | 2 |
| 2020 | 1 | 2 |
| 2021 | 0 | 0 |
| 2022 | 1 | 1 |
| 2023 | 0 | 1 |
| 2024 | 2 | 1 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Methods for categorizing and treating subjects having cystic fibrosis (CF) and at risk for severe pulmonary exacerbation19 Nov 2024US 12,146,875 B2National Jewish Health
- Methods for diagnosing or predicting chronic bronchitis3 Sep 2024US 12,078,640 B2The University of North Carolina at Chapel Hill
- ALX receptor ligands define a biochemical endotype for inflammation-based diseases6 Dec 2022US 11,519,911 B2The Brigham and Women S Hospital, Inc.
- Methods for categorizing and treating subjects at risk for pulmonary exacerbation and disease progression21 Jan 2020US 10,539,558 B2National Jewish Health
- Method for treating pulmonary exacerbation and disease progression in subjects having cystic fibrosis13 Nov 2018US 10,126,295 B2National Jewish Health
- Methods for Categorizing and Treating Subjects at Risk for Pulmonary Exacerbation and Disease Progression30 Jan 2025US 2025/0035617 A1National Jewish Health
- Systems and methods for monitoring respiratory gases12 Sep 2024US 2024/0298920 A1Masimo Corporation
- Biomarkers for the diagnosis of respiratory tract infections8 Jun 2023US 2023/0176074 A1B.R.A.H.M.S GmbH
- Methods for Categorizing and Treating Subjects at Risk for Pulmonary Exacerbation and Disease Progression30 Jun 2022US 2022/0205987 A1National Jewish Health
- Methods for Categorizing and Treating Subjects at Risk for Pulmonary Exacerbation and Disease Progression13 Aug 2020US 2020/0256859 A1National Jewish Health
Most cited
By later US patents
- Treatment of inflammatory disorders with STIgMA immunoadhesins25US 7,192,589 B2Genentech, Inc. · 2007
- Method for treating pulmonary exacerbation and disease progression in subjects having cystic fibrosis5US 10,126,295 B2National Jewish Health · 2018
- Naphthalene-based inhibitors of anti-apoptotic proteins5US 8,039,668 B2Burnham Institute for Medical Research · 2011
- Poultry viral materials and methods related thereto5US 8,679,504 B2University of Georgia Research Foundation, Inc. · 2014
- Use of A33 antigens and JAM-IT3US 7,741,056 B2Genentech, Inc. · 2010